

Christine M Durand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8428762/publications.pdf>

Version: 2024-02-01

100
papers

5,012
citations

147801

31
h-index

95266

68
g-index

101
all docs

101
docs citations

101
times ranked

6249
citing authors

#	ARTICLE	IF	CITATIONS
1	National Landscape of Human Immunodeficiency Virusâ€“Positive Deceased Organ Donors in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 2010-2019.	5.8	7
2	HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV. <i>American Journal of Transplantation</i> , 2022, 22, 853-864.	4.7	30
3	One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-Infected kidneys (MYTHIC) Trial. <i>Kidney International Reports</i> , 2022, 7, 241-250.	0.8	12
4	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. <i>Transplantation Direct</i> , 2022, 8, e1268.	1.6	14
5	Donors with human immunodeficiency virus and hepatitis C virus for solid organ transplantation: what's new. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 321-329.	3.1	2
6	Characterizing the landscape and impact of infections following kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 198-207.	4.7	27
7	Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses. <i>American Journal of Transplantation</i> , 2021, 21, 1838-1847.	4.7	39
8	A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action. <i>American Journal of Transplantation</i> , 2021, 21, 1754-1764.	4.7	56
9	Early steroid withdrawal in HIV-infected kidney transplant recipients: Utilization and outcomes. <i>American Journal of Transplantation</i> , 2021, 21, 717-726.	4.7	5
10	Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease preâ€“ or postâ€“liver transplant. <i>American Journal of Transplantation</i> , 2021, 21, 1780-1788.	4.7	14
11	Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis Câ€“Viremic Donors to Hepatitis Câ€“Negative Recipients: An Open-Label Nonrandomized Study. <i>Annals of Internal Medicine</i> , 2021, 174, 137-138.	3.9	38
12	Effects of COVID-19 pandemic on pediatric kidney transplant in the United States. <i>Pediatric Nephrology</i> , 2021, 36, 143-151.	1.7	20
13	Development of a Patient Reported Measure of Experimental Transplants with HIV and Ethics in the United States (PROMETHEUS). <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 28.	1.9	0
14	Pretransplant Hepatitis C Virus Treatment Decreases Access to High-quality Livers. <i>Transplantation Direct</i> , 2021, 7, e684.	1.6	1
15	Public discourse and policy change: Absence of harm from increased oversight and transparency in OPO performance. <i>American Journal of Transplantation</i> , 2021, 21, 2646-2652.	4.7	12
16	Clearing the hepatitis hurdle: Obstacles and opportunities in liver transplantation for people with HIV. <i>American Journal of Transplantation</i> , 2021, 21, 2931-2932.	4.7	1
17	Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine. <i>Transplantation Direct</i> , 2021, 7, e713.	1.6	11
18	Persistence of HIV after allogeneic bone marrow transplant in a dually-infected individual. <i>AIDS Research and Human Retroviruses</i> , 2021, , , .	1.1	0

#	ARTICLE	IF	CITATIONS
19	Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. <i>Aids</i> , 2021, 35, 2399-2401.	2.2	76
20	Patients'™ Experiences With HIV-positive to HIV-positive Organ Transplantation. <i>Transplantation Direct</i> , 2021, 7, e745.	1.6	1
21	Potential donor characteristics and decisions made by organ procurement organization staff: Results of a discrete choice experiment. <i>Transplant Infectious Disease</i> , 2021, 23, e13721.	1.7	5
22	Increasing the Donor Pool: Organ Transplantation from Donors with HIV to Recipients with HIV. <i>Annual Review of Medicine</i> , 2021, 72, 107-118.	12.2	4
23	Early Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic. <i>Transplantation</i> , 2021, 105, 170-176.	1.0	37
24	Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium. <i>Transplantation</i> , 2021, 105, 216-224.	1.0	18
25	Science Over Stigma: Lessons and Future Direction of HIV-to-HIV Transplantation. <i>Current Transplantation Reports</i> , 2021, 8, 314-323.	2.0	9
26	Rebound HIV viremia with meningoencephalitis following antiretroviral therapy interruption after allogeneic bone marrow transplant. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	2.1	1
27	Patient's™ Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site. <i>AJOB Empirical Bioethics</i> , 2020, 11, 40-52.	1.6	10
28	Clarifying the HOPE Act landscape: The challenge of donors with false'€ positive HIV results. <i>American Journal of Transplantation</i> , 2020, 20, 617-619.	4.7	13
29	Antithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients With Hepatitis C Virus. <i>Transplantation</i> , 2020, 104, 1294-1303.	1.0	5
30	Early Experiences With COVID-19 Testing in Transplantation. <i>Transplantation Direct</i> , 2020, 6, e572.	1.6	3
31	Haemopoietic cell transplantation in patients living with HIV. <i>Lancet HIV,the</i> , 2020, 7, e652-e660.	4.7	14
32	Evolving Impact of COVID'€19 on Transplant Center Practices and Policies in the United States. <i>Clinical Transplantation</i> , 2020, 34, e14086.	1.6	24
33	Brief Report: Willingness to Accept HIV-Infected and Increased Infectious Risk Donor Organs Among Transplant Candidates Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 88-92.	2.1	13
34	Similar Frequency and Inducibility of Intact Human Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. <i>Journal of Infectious Diseases</i> , 2020, 224, 258-268.	4.0	14
35	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. <i>Lancet HIV,the</i> , 2020, 7, e602-e610.	4.7	11
36	Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational study. <i>Lancet HIV,the</i> , 2020, 7, e611-e619.	4.7	25

#	ARTICLE	IF	CITATIONS
37	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2678-2687.	6.1	55
38	Single-cell transcriptional landscapes reveal HIV-driven aberrant host gene transcription as a potential therapeutic target. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	75
39	Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). <i>Blood</i> , 2020, 136, 1284-1297.	1.4	39
40	Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study. <i>American Journal of Transplantation</i> , 2020, 20, 2997-3007.	4.7	50
41	Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic. <i>American Journal of Transplantation</i> , 2020, 20, 3131-3139.	4.7	57
42	Early impact of COVID-19 on transplant center practices and policies in the United States. <i>American Journal of Transplantation</i> , 2020, 20, 1809-1818.	4.7	214
43	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2160-2166.	2.0	27
44	Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13194.	1.7	33
45	Lessons from the real world: HCV-infected donor kidney transplantation as standard practice. <i>American Journal of Transplantation</i> , 2019, 19, 2969-2970.	4.7	16
46	Challenges in solid organ transplantation in people living with HIV. <i>Intensive Care Medicine</i> , 2019, 45, 398-400.	8.2	8
47	Early experiences of independent advocates for potential HIV+ recipients of HIV+ donor organ transplants. <i>Clinical Transplantation</i> , 2019, 33, e13617.	1.6	3
48	Living Kidney Donation in Individuals with Hepatitis C and HIV Infection: Rationale and Emerging Evidence. <i>Current Transplantation Reports</i> , 2019, 6, 167-176.	2.0	1
49	Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers. <i>Current HIV/AIDS Reports</i> , 2019, 16, 191-203.	3.1	21
50	Reclaiming missed opportunities: a strategy of targeted direct-acting antiviral prophylaxis for HCV-seronegative recipients of HCV-seropositive donor kidneys. <i>Transplant International</i> , 2019, 32, 690-692.	1.6	2
51	The future of HIV Organ Policy Equity Act is now. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 434-440.	1.6	13
52	Bypassing the bottleneck: intentional hepatitis C transmission with organ transplant. <i>Journal of Clinical Investigation</i> , 2019, 129, 3038-3040.	8.2	1
53	Moving from the HIV Organ Policy Equity Act to HIV Organ Policy Equity in action. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 271-278.	1.6	26
54	Reply. <i>Hepatology</i> , 2018, 67, 1183-1184.	7.3	0

#	ARTICLE	IF	CITATIONS
55	Utilization of hepatitis C virus RNAâ€‘positive donor liver for transplant to hepatitis C virus RNAâ€‘negative recipient. Liver Transplantation, 2018, 24, 140-143.	2.4	32
56	<scp>HIV</scp>+ deceased donor referrals: A national survey of organ procurement organizations. Clinical Transplantation, 2018, 32, e13171.	1.6	14
57	Pro: Use of Hepatitis C Virusâ€‘Positive Donors Should Be Considered Standard of Care. Clinical Liver Disease, 2018, 12, 100-104.	2.1	12
58	Willingness to Donate Organs Among People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, e30-e36.	2.1	26
59	The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States. Annals of Internal Medicine, 2018, 168, 702.	3.9	169
60	Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virusâ€‘Infected Donors to Noninfected Recipients. Annals of Internal Medicine, 2018, 168, 533.	3.9	258
61	Organs from deceased donors with false-positive HIV screening tests: An unexpected benefit of the HOPE act. American Journal of Transplantation, 2018, 18, 2579-2586.	4.7	30
62	Solid Organ Transplantation for HIV-Infected Individuals. Current Treatment Options in Infectious Diseases, 2018, 10, 107-120.	1.9	23
63	Perceptions, motivations, and concerns about living organ donation among people living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1595-1599.	1.2	10
64	Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. Transplant Infectious Disease, 2018, 20, e12982.	1.7	12
65	Knowledge, attitudes, and planned practice of <scp>HIV</scp>-positive to <scp>HIV</scp>-positive transplantation in <scp>US</scp> transplant centers. Clinical Transplantation, 2018, 32, e13365.	1.6	31
66	Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy. Transplantation, 2018, 102, 2088-2095.	1.0	36
67	Expanding the Use of Organs From Hepatitis C-Viremic Donors. Transplantation, 2018, 102, 546-547.	1.0	4
68	No recovery of replication-competent HIV-1 from human liver macrophages. Journal of Clinical Investigation, 2018, 128, 4501-4509.	8.2	41
69	Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma. Hepatology, 2017, 66, 661-663.	7.3	15
70	Changes in Utilization and Discard of Hepatitis Câ€‘Infected Donor Livers in the Recent Era. American Journal of Transplantation, 2017, 17, 519-527.	4.7	95
71	Epsteinâ€‘Barr virus and renal transplantation. Transplantation Reviews, 2017, 31, 55-60.	2.9	39
72	Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection. Immunity, 2017, 47, 766-775.e3.	14.3	160

#	ARTICLE	IF	CITATIONS
73	Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. <i>Journal of Clinical Investigation</i> , 2017, 127, 651-656.	8.2	64
74	Single-Center Experience in Pre-transplant Hepatitis C Virus (HCV) Treatment Among Living Donor Liver Transplant Candidates: Bridging the Direct-Acting Antivirals (DAA). <i>Annals of Transplantation</i> , 2017, 22, 570-574.	0.9	2
75	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016, 22, 446-458.	2.4	73
76	Realizing HOPE: The Ethics of Organ Transplantation From HIV-Positive Donors. <i>Annals of Internal Medicine</i> , 2016, 165, 138.	3.9	50
77	Hepatitis C following liver transplantation. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 346-352.	3.1	1
78	The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. <i>Blood</i> , 2016, 127, 2007-2017.	1.4	158
79	False-positive hepatitis C virus serology after placement of a ventricular assistance device. <i>Transplant Infectious Disease</i> , 2016, 18, 146-149.	1.7	6
80	Antimicrobial Access in the 21st Century: Delays and Critical Shortages. <i>Annals of Internal Medicine</i> , 2016, 165, 53.	3.9	3
81	A Human Immunodeficiency Virus Controller With a Large Population of CD4+CD8+ Double-Positive T Cells. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv039.	0.9	3
82	Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. <i>Nature</i> , 2015, 517, 381-385.	27.8	469
83	<i>Pasteurella multocida</i> infection in solid organ transplantation. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 235-240.	9.1	38
84	Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. <i>Journal of Clinical Investigation</i> , 2015, 125, 1901-1912.	8.2	340
85	New modalities in the treatment of HCV in pre and post - transplantation setting. <i>Turkish Journal of Gastroenterology</i> , 2015, 26, 204-213.	1.1	1
86	Implications of Treating Hepatitis C Virus Infection Among Patients Awaiting Cadaveric Liver Transplant: A Single-Center Experience. <i>Experimental and Clinical Transplantation</i> , 2015, 13, 7-10.	0.5	4
87	A 70-Year-Old Kidney Transplant Recipient Presenting With Persistent Leg Cellulitis. <i>Clinical Infectious Diseases</i> , 2014, 59, 688-688.	5.8	0
88	New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. <i>Nature Medicine</i> , 2014, 20, 425-429.	30.7	436
89	HIV and Stem Cell Transplantation. <i>Current Infectious Disease Reports</i> , 2014, 16, 424.	3.0	6
90	Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 596-604.	6.4	38

#	ARTICLE	IF	CITATIONS
91	Dual zinc-finger nucleases block HIV infection. <i>Blood</i> , 2014, 123, 2-3.	1.4	8
92	Hematopoietic stem cell transplantation in HIV-1-infected individuals. <i>Current Opinion in Oncology</i> , 2013, 25, 180-186.	2.4	12
93	Detection of Cytomegalovirus DNA in Plasma as an Adjunct Diagnostic for Gastrointestinal Tract Disease in Kidney and Liver Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2013, 57, 1550-1559.	5.8	63
94	Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. <i>Journal of Clinical Investigation</i> , 2013, 123, 3848-3860.	8.2	120
95	HIV-1 DNA Is Detected in Bone Marrow Populations Containing CD4+ T Cells but Is not Found in Purified CD34+ Hematopoietic Progenitor Cells in Most Patients on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2012, 205, 1014-1018.	4.0	102
96	Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation. <i>Immunity</i> , 2012, 36, 491-501.	14.3	680
97	Developing strategies for HIV-1 eradication. <i>Trends in Immunology</i> , 2012, 33, 554-562.	6.8	87
98	Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. <i>Journal of Clinical Virology</i> , 2011, 51, 195-198.	3.1	9
99	HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia. <i>Aids</i> , 2010, 24, 2405-2408.	2.2	12
100	With Jaundiced Eyes. <i>American Journal of Medicine</i> , 2009, 122, 21-23.	1.5	5